296 related articles for article (PubMed ID: 35215980)
21. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
Front Immunol; 2022; 13():829665. PubMed ID: 35154152
[TBL] [Abstract][Full Text] [Related]
22. Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant.
Yu X; Qi X; Cao Y; Li P; Lu L; Wang P; Feng Y; Yang J; Wei H; Guo L; Sun M; Liu Q; Lv J; Feng Y
Emerg Microbes Infect; 2022 Dec; 11(1):749-752. PubMed ID: 35176972
[TBL] [Abstract][Full Text] [Related]
23. COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era.
Volkan E
Mol Biotechnol; 2021 Oct; 63(10):885-897. PubMed ID: 34145550
[TBL] [Abstract][Full Text] [Related]
24. Optimization of SARS-CoV-2 Spike Protein Expression in the Silkworm and Induction of Efficient Protective Immunity by Inoculation With Alum Adjuvants.
Masuda A; Lee JM; Miyata T; Mon H; Sato K; Oyama K; Sakurai Y; Yasuda J; Takahashi D; Ueda T; Kato Y; Nishida M; Karasaki N; Kakino K; Ebihara T; Nagasato T; Hino M; Nakashima A; Suzuki K; Tonooka Y; Tanaka M; Moriyama T; Nakatake H; Fujita R; Kusakabe T
Front Immunol; 2021; 12():803647. PubMed ID: 35095889
[TBL] [Abstract][Full Text] [Related]
25. Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model.
Kurup D; Malherbe DC; Wirblich C; Lambert R; Ronk AJ; Zabihi Diba L; Bukreyev A; Schnell MJ
PLoS Pathog; 2021 Mar; 17(3):e1009383. PubMed ID: 33765062
[TBL] [Abstract][Full Text] [Related]
26. Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants.
Fan S; Xiao K; Li D; Zhao H; Zhang J; Yu L; Chang P; Zhu S; Xu X; Liao Y; Ji T; Jiang G; Yan D; Zeng F; Duan S; Xia B; Wang L; Yang F; He Z; Song Y; Cui P; Li X; Zhang Y; Zheng B; Zhang Y; Xu W; Li Q
Emerg Microbes Infect; 2022 Dec; 11(1):212-226. PubMed ID: 34931939
[TBL] [Abstract][Full Text] [Related]
27. COVID-19: Significance of antibodies.
Assadiasl S; Fatahi Y; Zavvar M; Nicknam MH
Hum Antibodies; 2020; 28(4):287-297. PubMed ID: 32986664
[TBL] [Abstract][Full Text] [Related]
28. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M
Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
[TBL] [Abstract][Full Text] [Related]
30. Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines.
Zhao X; Zhang R; Qiao S; Wang X; Zhang W; Ruan W; Dai L; Han P; Gao GF
N Engl J Med; 2022 Jul; 387(3):277-280. PubMed ID: 35793198
[No Abstract] [Full Text] [Related]
31. A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine.
Yue L; Xie T; Yang T; Zhou J; Chen H; Zhu H; Li H; Xiang H; Wang J; Yang H; Zhao H; Wei X; Zhang Y; Xie Z
J Med Virol; 2022 Jan; 94(1):35-38. PubMed ID: 34516026
[No Abstract] [Full Text] [Related]
32. Developing Immunity Testing for SARS-CoV-2 and Other Novel Vaccines-Correlates of Immunogenicity Parameters with Protection.
Vajo Z
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215791
[TBL] [Abstract][Full Text] [Related]
33. Alum/CpG adjuvant promotes immunogenicity of inactivated SARS-CoV-2 Omicron vaccine through enhanced humoral and cellular immunity.
Zheng X; Yang R; Zhao Y; Zhang Y; Yuan G; Li W; Xiao Z; Dong X; Ma M; Guo Y; Wang W; Zhao X; Yang H; Qiu S; Peng Z; Liu A; Yu S; Zhang Y
Virology; 2024 Jun; 594():110050. PubMed ID: 38479071
[TBL] [Abstract][Full Text] [Related]
34. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
Wang Y
EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
[No Abstract] [Full Text] [Related]
35. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2.
Sapkal GN; Yadav PD; Ella R; Deshpande GR; Sahay RR; Gupta N; Vadrevu KM; Abraham P; Panda S; Bhargava B
J Travel Med; 2021 Jun; 28(4):. PubMed ID: 33772577
[No Abstract] [Full Text] [Related]
36. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
[TBL] [Abstract][Full Text] [Related]
37. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
38. CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge.
Lien CE; Lin YJ; Chen C; Lian WC; Kuo TY; Campbell JD; Traquina P; Lin MY; Liu LT; Chuang YS; Ko HY; Liao CC; Chen YH; Jan JT; Ma HH; Sun CP; Lin YS; Wu PY; Wang YC; Tao MH; Lin YL
Sci Rep; 2021 Apr; 11(1):8761. PubMed ID: 33888840
[TBL] [Abstract][Full Text] [Related]
39. A Highly Conserved Peptide Vaccine Candidate Activates Both Humoral and Cellular Immunity Against SARS-CoV-2 Variant Strains.
Gao F; Huang J; Li T; Hu C; Shen M; Mu S; Luo F; Song S; Hao Y; Wang W; Han X; Qian C; Wang Y; Wu R; Li L; Li S; Jin A
Front Immunol; 2021; 12():789905. PubMed ID: 34950151
[TBL] [Abstract][Full Text] [Related]
40. Plasma Neutralization of the SARS-CoV-2 Omicron Variant.
Schmidt F; Muecksch F; Weisblum Y; Da Silva J; Bednarski E; Cho A; Wang Z; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
N Engl J Med; 2022 Feb; 386(6):599-601. PubMed ID: 35030645
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
